|Bid||15.62 x 0|
|Ask||15.64 x 0|
|Day's Range||15.61 - 15.93|
|52 Week Range||8.80 - 17.13|
|Beta (5Y Monthly)||0.05|
|PE Ratio (TTM)||37.62|
|Earnings Date||Apr 30, 2021|
|Forward Dividend & Yield||0.10 (0.77%)|
|Ex-Dividend Date||May 31, 2021|
|1y Target Est||N/A|
Geron (GERN) delivered earnings and revenue surprises of 11.11% and 9.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron (NASDAQ: GERN) is a small biotech that's experienced plenty of ups and downs. In this Motley Fool Live video recorded on Aug. 18, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss what investors need from Geron going forward. What do you think about the company's update and what should investors be watching going forward?